financetom
Business
financetom
/
Business
/
Mason Resources Acquires Additional Securities of NorthX Nickel
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mason Resources Acquires Additional Securities of NorthX Nickel
Feb 14, 2025 6:04 AM

08:38 AM EST, 02/14/2025 (MT Newswires) -- Mason Resources ( MGPHF ) said overnight Thursday that it acquired additional securities in NorthX Nickel ( NXNIF )

Mason said it acquired over 1.2 million subscription receipts of NorthX, with each subscription receipt comprising one share and one warrant of NorthX. Each warrant can be exercised at $0.075 per share until Feb. 10, 2028.

Assuming the escrow release condition is satisfied, Mason would acquire over 1.2 million shares and 1.2 million warrants of NorthX, representing a decrease in its ownership and control of about 4.73% on a non-diluted basis and 6.18% on a partially-diluted basis.

Immediately prior to the acquisition of the Subscription Receipts, Mason held 14.55% of NorthX shares on a non-diluted basis and 25.41% on a partially-diluted basis.

After the acquisition, Mason would hold 9.8% of the shares on a non-diluted basis and 17.9% on a partially-diluted basis.

Mason said it acquired the subscription receipts for investment purposes and not for a potential change of control of NorthX.

Mason also owns stakes in Black Swan Graphene (SWAN.V) and Nouveau Monde Graphite ( NMG ) .

Mason's share price soared 15% on Thursday to $0.075 on the TSXV.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Iovance Says Amtagvi Shows 49% Response Rate in Real-World Skin Cancer Study
Iovance Says Amtagvi Shows 49% Response Rate in Real-World Skin Cancer Study
Jul 14, 2025
08:25 AM EDT, 07/14/2025 (MT Newswires) -- Iovance Biotherapeutics ( IOVA ) said Monday its drug Amtagvi led to a 48.8% objective response rate in a retrospective real-world study of 41 patients with skin cancer. Patients treated earlier, after two or fewer prior therapies, saw a response rate of 60.9%, compared to 33.3% among those with three or more previous...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Fury Gold Mines Launches 2025 Drilling Campaign at Committee Bay Project in Nunavut
Fury Gold Mines Launches 2025 Drilling Campaign at Committee Bay Project in Nunavut
Jul 14, 2025
08:26 AM EDT, 07/14/2025 (MT Newswires) -- Fury Gold Mines ( FURY ) said Monday that it has begun its 2025 exploration drilling program totaling 5,000 meters at the Committee Bay project in Nunavut. The campaign will focus on expanding the Three Bluffs Shear Zone target, testing regional shear zones along the southern contact of Raven shear zone, and testing...
Becton's Biosciences And Diagnostics Arm Slated To Join Waters In $17.5 Billion Merger
Becton's Biosciences And Diagnostics Arm Slated To Join Waters In $17.5 Billion Merger
Jul 14, 2025
Becton, Dickinson and Company ( BDX )  has agreed to combine its Biosciences & Diagnostic Solutions business with Waters Corporation ( WAT ) . The agreement is structured as a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion. The transaction is expected to close around the end of the first quarter of calendar year 2026. Biosciences segment offers immunology and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved